Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nishikant Nandlal Mankar"'
Autor:
Pratik Pradeep Wadivkar, Vijay Ramakrishna Zad, Kalpana Unind Shah, Monali Pradeep Vakharia, Nishikant Nandlal Mankar
Publikováno v:
International Journal of Pharmacology and Clinical Sciences. 5:55-61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f81f406d412bc80310fa57be2077688f
https://doi.org/10.5530/ijpcs.5.2.4
https://doi.org/10.5530/ijpcs.5.2.4
Publikováno v:
International Journal of Basic and Clinical Pharmacology. :1421-1424
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2eb2ce5fc121698714e188386b25d28d
https://doi.org/10.18203/2319-2003.ijbcp20162446
https://doi.org/10.18203/2319-2003.ijbcp20162446
Autor:
Monali Pradeep Vakharia, Pratik Pradeep Wadivkar, Nishikant Nandlal Mankar, Vijay Ramkrishna Zad
Publikováno v:
International Journal of Basic and Clinical Pharmacology. :1349-1352
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06c559e359abba317008b9d04e87a559
https://doi.org/10.18203/2319-2003.ijbcp20162434
https://doi.org/10.18203/2319-2003.ijbcp20162434
Autor:
Nishikant Nandlal Mankar, Pratik Pradeep Wadivkar, Vijay Ramakrishna Zad, Monali Pradeep Vakharia
Publikováno v:
International Journal of Basic & Clinical Pharmacology. 7:1522
Background: Beta blockers have been used in the treatment of hypertension, since last four decades and are widely accepted as the first-line treatment for hypertension. Nebivolol, a third generation β-blocker has highest β1 selectivity and is devoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8aca0e6fe64e230aa5f5a8f48993bb9a
https://doi.org/10.18203/2319-2003.ijbcp20183018
https://doi.org/10.18203/2319-2003.ijbcp20183018
Autor:
Nishikant Nandlal Mankar, Pratik Pradeep Wadivkar, Vijay Ramakrishna Zad, Monali Pradeep Vakharia, Kalpana Unind Shah
Publikováno v:
International Journal of Research in Medical Sciences. 5:150
Background: Diabetes mellitus is a progressive disease characterised by declining β-cell function. Cornerstone of effective management of T2DM is maintaining strict glycaemic control through agency of various oral hypo-glycaemic agents (OHAs). Metfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::773b27dce81865280d1407aa96c6eea9
https://doi.org/10.18203/2320-6012.ijrms20164539
https://doi.org/10.18203/2320-6012.ijrms20164539